MARQUES, Sérgio Manuel, Lucie ŠUPOLÍKOVÁ, Lenka MOLČANOVÁ, Karel ŠMEJKAL, David BEDNÁŘ and Iva SLANINOVÁ. Screening of Natural Compounds as P-Glycoprotein Inhibitors against Multidrug Resistance. BIOMEDICINES. BASEL: MDPI, 2021, vol. 9, No 4, p. 1-22. ISSN 2227-9059. Available from: https://dx.doi.org/10.3390/biomedicines9040357.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Screening of Natural Compounds as P-Glycoprotein Inhibitors against Multidrug Resistance
Authors MARQUES, Sérgio Manuel (620 Portugal, belonging to the institution), Lucie ŠUPOLÍKOVÁ (203 Czech Republic, belonging to the institution), Lenka MOLČANOVÁ (703 Slovakia, belonging to the institution), Karel ŠMEJKAL (203 Czech Republic, belonging to the institution), David BEDNÁŘ (203 Czech Republic, belonging to the institution) and Iva SLANINOVÁ (203 Czech Republic, guarantor, belonging to the institution).
Edition BIOMEDICINES, BASEL, MDPI, 2021, 2227-9059.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30104 Pharmacology and pharmacy
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 4.757
RIV identification code RIV/00216224:14110/21:00121577
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3390/biomedicines9040357
UT WoS 000642790800001
Keywords in English flavonoids; molecular dynamics; molecular docking; multidrug resistance; natural compounds; P-glycoprotein; structure-based virtual screening
Tags 14110513, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Michaela Hylsová, Ph.D., učo 211937. Changed: 15/2/2023 23:15.
Abstract
Multidrug resistance (MDR) is a common problem when fighting cancer with chemotherapy. P-glycoprotein (P-gp, or MDR1) is an active pump responsible for the efflux of xenobiotics out of the cell, including anti-cancer drugs. It is a validated target against MDR. No crystal structure of the human P-gp is available to date, and only recently several cryo-EM structures have been solved. In this paper, we present a comprehensive computational approach that includes constructing the full-length three-dimensional structure of the human P-gp and its refinement using molecular dynamics. We assessed its flexibility and conformational diversity, compiling a dynamical ensemble that was used to dock a set of lignan compounds, previously reported as active P-gp inhibitors, and disclose their binding modes. Based on the statistical analysis of the docking results, we selected a system for performing the structure-based virtual screening of new potential P-gp inhibitors. We tested the method on a library of 87 natural flavonoids described in the literature, and 10 of those were experimentally assayed. The results reproduced the theoretical predictions only partially due to various possible factors. However, at least two of the predicted natural flavonoids were demonstrated to be effective P-gp inhibitors. They were able to increase the accumulation of doxorubicin inside the human promyelocytic leukemia HL60/MDR cells overexpressing P-gp and potentiate the antiproliferative activity of this anti-cancer drug.
Links
LM2018121, research and development projectName: Výzkumná infrastruktura RECETOX (Acronym: RECETOX RI)
Investor: Ministry of Education, Youth and Sports of the CR, RECETOX RI
LM2018131, research and development projectName: Česká národní infrastruktura pro biologická data (Acronym: ELIXIR-CZ)
Investor: Ministry of Education, Youth and Sports of the CR, Czech National Infrastructure for Biological Data
LM2018140, research and development projectName: e-Infrastruktura CZ (Acronym: e-INFRA CZ)
Investor: Ministry of Education, Youth and Sports of the CR
MUNI/A/1325/2020, interní kód MUName: Biomedicínské vědy
Investor: Masaryk University
814418, interní kód MUName: Synthetic biology-guided engineering of Pseudomonas putida for biofluorination (Acronym: SinFonia)
Investor: European Union, Leadership in enabling and industrial technologies (LEIT) (Industrial Leadership)
PrintDisplayed: 27/4/2024 04:51